Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Kyle LaHucik

Senior Reporter

Nearly six years to the day after offloading its factor XI inhibitor to Blackstone Life Sciences, Novartis is swooping up the monoclonal antibody for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

What will pharma's share buyback shopping spree mean for M&A?

Pfizer’s prostate cancer data leak shows promising results in early-stage study

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Vertex operations chief Stuart Arbuckle to retire

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos